- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04552288
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
Phase II Study of IL-5-receptor-alpha-chain (IL-5Rα) Inhibition With Benralizumab for Eosinophil-Related Cutaneous Adverse Events in Cancer Patients
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Alina Markova, MD
- Phone Number: 646-608-2342
- Email: markovaa@mskcc.org
Study Contact Backup
- Name: Mario E. Lacouture, MD
- Phone Number: 646-608-2337
- Email: LacoutuM@mskcc.org
Study Locations
-
-
New Jersey
-
Basking Ridge, New Jersey, United States, 07920
- Memorial Sloan Kettering Cancer Center
-
-
New York
-
Commack, New York, United States, 11725
- Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)
-
Harrison, New York, United States, 10604
- Memorial Sloan Kettering Westchester
-
Hauppauge, New York, United States, 11788
- Memorial Sloan Kettering Cancer Center Suffolk - Hauppauge (Limited Protocol Activities)
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must have pathologically or cytologically confirmed solid or hematologic cancers.
OR
- Patient is receiving alpelisib for PIK3CA-Related Overgrowth Spectrum disorder.
- Female and male aged 18 to 85 years, inclusively, at the time of Week 0/Day 1 of treatment.
Patients must have a therapy-related CTCAE grade 2/3 (See Appendix A)cutaneous adverse event defined as any cutaneous reaction listed below and blood eosinophil counts of at least .3 K/mcl.
- Rash maculo-papular
- Bullous dermatitis
- Pruritus
- Urticaria
- Eczema
- Patients must plan to continue on culprit drugs (cancer patients).
- Patients planning to receive alpelisib indicated for PIK3CA-Related Overgrowth
Spectrum disorder OR patients receiving immunotherapy and/or targeted therapy, including but not limited to the following agents, will be eligible for inclusion:
- Immunotherapies: ipilimumab, nivolumab, pembrolizumab, avelumab, durvalumab, atezolizumab tremelimumab.
Targeted therapies: trastuzumab, pertuzumab, alpelisib, osimertinib, everolimus, temsirolimus, sorafenib, regorafenib.
- Patients using topicals/orals for indication of skin rash/pruritus for at least 7 days should continue using these drugs for the study duration
- Adequate bone marrow, liver and renal function:
- Total bilirubin ≤ 1.5 x the upper limit of normal (ULN)
- Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) ≤ 2.5 x ULN (≤ 5 x ULN for subjects with liver involvement of their cancer)
- Serum creatinine ≤ 1.8 xULN or calculated creatinine clearance >45 ml/min
Platelet count > 50 K/mcL , hemoglobin (Hb) > 8 g/dL, absolute neutrophil count (ANC) >1.0 K/mcL. Blood transfusion to meet the inclusion criteria will not be allowed.
- ECOG performance status 0-1 (see Appendix C).
- Subjects must be able to understand and be willing to sign the written informed consent form. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure.
- Female patients are authorized to participate if they meet the following criteria:
- Women of child bearing potential must meet both of the following conditions:
- Have a negative serum pregnancy test prior to enrollment and within 14 days prior to administration of the investigational product (IP).
- Patient must use an effective form of birth control (confirmed by the Investigator) throughout the study duration and within 16 weeks after last dose of IP.
- Female subjects who cannot bear children as evidenced by one or more of the following:
- Bilateral Oophorectomy
- Bilateral Salpingectomy
- Bilateral Salpingectomy-Oophorectomy
- Hysterectomy
- Menopause (no menses ≥ 1 year prior to treatment)
Surgical Sterilization (i.e., tubal ligation or blockage) Note: If criteria not met, patient should be regarded as having child bearing potential
- Subject must be able to receive a subcutaneous injection.
- New/worsening ercAE within 90 days prior to study enrollment. Note: This assessment will be performed by the treating investigator.
Exclusion Criteria:
- Concurrent use of another investigational drug or device for the ercAE (i.e., outside of study treatment) during, or within 4 weeks of treatment.
- Patients receiving prednisone ≥ 20mg a day.
- Known use of anti-IL-5 agents or biologics for the treatment of asthma which are known to decrease blood eosinophil levels.
- Patients cannot use new topicals or medications for indication of pruritus or skin rash
- Known history of anaphylaxis to biologic therapy.
- A helminthic parasitic infection diagnosed within 24 weeks prior to the first treatment, that had not been treated with, or has failed to respond to, standard of care therapy.
- Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy.
- Active infection that would impair the ability of the patient to receive study treatment.
- Women who are pregnant or breast-feeding.
- Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation.
Receipt of live attenuated vaccines 30 days prior to the date of randomization
° Receipt of inactive/killed vaccinations (e.g., inactive influenza) is allowed provided they were not administered within 1 week before/after any investigational product administration.
- Known history of allergy or reaction to the investigational product formulation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Participants with eosinophil-related cutaneous events
Study participants will have grade 2/3 eosinophil-related cutaneous adverse events
|
All eligible patients will receive a benralizumab dose of 30 mg SC administered by a healthcare provider once every 4 weeks for the first 3 doses, followed by once every 8 weeks for 3 additional doses.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent reduction in CTCAE grade 2/3 eosinophil-related cutaneous adverse events
Time Frame: 4 weeks
|
To evaluate the percent reduction in CTCAE grade 2/3 eosinophil-related cutaneous adverse events to grade ≤1 resulting from checkpoint inhibitors (CPIs) or targeted therapies with absolute blood eosinophil counts of at least .3
K/mcl.
|
4 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Mario E. Lacouture, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-344
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
Clinical Trials on Benralizumab
-
AstraZenecaMedImmune LLCCompletedModerate to Very Severe Chronic Obstructive Pulmonary DiseaseUnited States, Denmark, France, Sweden, Thailand, Vietnam, Belgium, Brazil, Peru, Philippines, Turkey, Taiwan, Argentina, Australia, Israel, Poland, Ukraine, Slovenia, Serbia, Mexico, Bulgaria, Colombia, New Zealand, Chile, Norway, Croatia
-
AstraZenecaIqvia Pty LtdTerminatedChronic Spontaneous UrticariaUnited States, Germany, Korea, Republic of, Spain, Bulgaria, Poland, Japan
-
AstraZenecaIqvia Pty LtdTerminatedAtopic DermatitisUnited States, France, Korea, Republic of, Spain, Czechia, Bulgaria, Australia, Poland
-
AstraZenecaMedImmune LLCCompletedModerate to Very Severe Chronic Obstructive Pulmonary DiseaseUnited States, Canada, Germany, Italy, Netherlands, Spain, United Kingdom, Poland, Japan, Austria, Korea, Republic of, Russian Federation, South Africa, Czechia, Hungary, Romania, Switzerland
-
MedImmune LLCMedImmune LtdCompletedAsthmaUnited States, Brazil, Bulgaria, Mexico, Peru, Poland, Russian Federation, Argentina, Canada, Colombia
-
Instituto de Investigación Sanitaria de la Fundación...CompletedAsthma; EosinophilicSpain
-
MedImmune LLCCompleted
-
AstraZenecaCompletedNasal Polyps | Severe Eosinophilic AsthmaUnited States, France, Italy, Spain, Germany, Japan
-
Jonathan A. Bernstein, MDCompletedChronic Idiopathic UrticariaUnited States
-
AstraZenecaCompletedAsthmaUnited States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom